Regeneron licenses tech to Sanofi in $21.5M deal

Sanofi-Aventis has agreed to make five annual payments of at least $4.3 million to Regeneron Pharmaceuticals in exchange for the rights to use its Velocigene technology. Regeneron posted losses of $125 million in the last fiscal year. The technology will be used to develop knock-out and transgenic models of gene function for target genes identified by Sanofi-Aventis. Sanofi-Aventis will use these models for its internal research programs, outside the scope of its antibody collaboration with Regeneron.

- here's the press release
- read the report from Business in the Burbs

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.